Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Summary

A growing body of literature supports the role of angiogenesis in the development and spread of a variety of human cancers including prostate cancer. * Vascular endothelial growth factor (VEGF) expression is low in normal prostate tissue, but markedly increased in tumor tissues, and has a positive association with tumor stage and grade * Plasma VEGF levels are significantly elevated in patients with hormone refractory prostate cancer (HRPC) compared to those patients with localized disease and have been associated with disease progression in other cancer patient population. * The Cancer and Leukemic Group-B demonstrated that VEGF levels correlate with survival. Pazopanib is a potent multi-target receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptors.

Timeline

Start

2009-07

Primary completion

2012-10

Completion

2012-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment”

Drugs

Indications